2 ms·
This isn't unusual for a pharma company, or any other big company for that matter. Transfer/keep/develop the IP in a low-tax jurisdiction and then have their U
by Scoundreller 11y ago
This isn't unusual for a pharma company, or any other big company for that matter.
Transfer/keep/develop the IP in a low-tax jurisdiction and then have their US/Canadian/whatever division pay a licensing fee to the corp in that low-tax jurisdiction.